Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,762
  • Shares Outstanding, K 61,948
  • Annual Sales, $ 16,150 K
  • Annual Income, $ -77,330 K
  • EBIT $ -69 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.15
  • Price/Sales 4.11
  • Price/Cash Flow N/A
  • Price/Book 0.53

Options Overview Details

View History
  • Implied Volatility 709.84% ( +522.87%)
  • Historical Volatility 97.65%
  • IV Percentile 99%
  • IV Rank 79.52%
  • IV High 889.90% on 03/17/25
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 1,794
  • Open Int (30-Day) 2,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.32
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9200 +31.52%
on 04/21/25
1.3300 -9.02%
on 05/02/25
+0.2761 (+29.56%)
since 04/16/25
3-Month
0.8332 +45.22%
on 04/07/25
1.4000 -13.57%
on 02/18/25
-0.1100 (-8.33%)
since 02/14/25
52-Week
0.8332 +45.22%
on 04/07/25
5.3899 -77.55%
on 11/11/24
-2.9600 (-70.98%)
since 05/16/24

Most Recent Stories

More News
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

PYXS : 1.2100 (+9.01%)
Pyxis Oncology to Participate in Two Upcoming Investor Conferences

PYXS : 1.2100 (+9.01%)
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the upcoming European...

PYXS : 1.2100 (+9.01%)
BVAXF : 0.0255 (+0.79%)
BIOV.CN : 0.0350 (unch)
SONA.CN : 0.3500 (+2.94%)
GRAL : 39.91 (+2.36%)
SNANF : 0.2548 (+4.17%)
ADPT : 9.05 (+1.57%)
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

PYXS : 1.2100 (+9.01%)
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

For Immediate ReleaseChicago, IL – April 24, 2025 – Today, Zacks Equity Research discusses Aurinia Pharmaceuticals AUPH, Heron Therapeutics HRTX, Esperion Therapeutics ESPR, Pyxis Oncology PYXS and...

ESPR : 0.8018 (+3.17%)
PSTV : 0.4200 (-17.09%)
PYXS : 1.2100 (+9.01%)
AUPH : 8.19 (+0.49%)
HRTX : 1.9700 (+5.35%)
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

PYXS : 1.2100 (+9.01%)
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

PYXS : 1.2100 (+9.01%)
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PYXS : 1.2100 (+9.01%)
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

PYXS : 1.2100 (+9.01%)
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

PYXS : 1.2100 (+9.01%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.3567
2nd Resistance Point 1.2833
1st Resistance Point 1.2467
Last Price 1.2100
1st Support Level 1.1367
2nd Support Level 1.0633
3rd Support Level 1.0267

See More

52-Week High 5.3899
Fibonacci 61.8% 3.6492
Fibonacci 50% 3.1116
Fibonacci 38.2% 2.5739
Last Price 1.2100
52-Week Low 0.8332

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar